Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis

Thromb Haemost. 1992 Dec 7;68(6):648-51.

Abstract

We describe the case of a 64-year-old woman with isolated severe factor X deficiency associated with kappa light chain myeloma. At the time of diagnosis there was no evidence for amyloidosis. Complete remission (CR) of myeloma as well as normalization of factor X levels were achieved after cytostatic chemotherapy. Subsequently, factor X deficiency recurred twice without any evidence for relapse of myeloma. The first time factor X normalized again following cytostatic treatment, the second time, however, factor X deficiency was refractory to chemotherapy. Finally, relapse of myeloma became evident associated with rapidly progressing, systemic amyloidosis, which was fatal within a few months. Initially, factor X infusion studies showed a normal recovery, but when amyloidosis became overt the recovery decreased to 0%. We assume that factor X deficiency was due to a binding of factor X to kappa light chains associated with the proliferation of the malignant myeloma cell clone.

Publication types

  • Case Reports

MeSH terms

  • Amyloidosis / etiology*
  • Antineoplastic Agents / therapeutic use*
  • Blood Coagulation Tests
  • Factor X / administration & dosage
  • Factor X / metabolism*
  • Factor X / pharmacokinetics
  • Factor X Deficiency / complications
  • Factor X Deficiency / drug therapy*
  • Female
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Neoplasm Recurrence, Local / complications
  • Recurrence
  • Remission Induction / methods
  • Time Factors

Substances

  • Antineoplastic Agents
  • Factor X